These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19935776)

  • 1. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma.
    Adamina M; Rosenthal R; Weber WP; Frey DM; Viehl CT; Bolli M; Huegli RW; Jacob AL; Heberer M; Oertli D; Marti W; Spagnoli GC; Zajac P
    Mol Ther; 2010 Mar; 18(3):651-9. PubMed ID: 19935776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
    Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
    Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
    Oertli D; Marti WR; Zajac P; Noppen C; Kocher T; Padovan E; Adamina M; Schumacher R; Harder F; Heberer M; Spagnoli GC
    Hum Gene Ther; 2002 Mar; 13(4):569-75. PubMed ID: 11874634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules.
    Zajac P; Schütz A; Oertli D; Noppen C; Schaefer C; Heberer M; Spagnoli GC; Marti WR
    Cancer Res; 1998 Oct; 58(20):4567-71. PubMed ID: 9788602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope.
    Zajac P; Oertli D; Spagnoli GC; Noppen C; Schaefer C; Heberer M; Marti WR
    Int J Cancer; 1997 May; 71(3):491-6. PubMed ID: 9139889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
    Nagorsen D; Panelli M; Dudley ME; Finkelstein SE; Rosenberg SA; Marincola FM
    Gene Ther; 2003 Sep; 10(20):1754-65. PubMed ID: 12939642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
    Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
    Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
    Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Topalian SL; Sherry RM; Restifo NP; Wunderlich JR; Seipp CA; Rogers-Freezer L; Morton KE; Mavroukakis SA; Gritz L; Panicali DL; White DE
    Clin Cancer Res; 2003 Aug; 9(8):2973-80. PubMed ID: 12912944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
    Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
    J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy.
    Spagnoli GC; Zajac P; Marti WR; Oertli D; Padovan E; Noppen C; Kocher T; Adamina M; Heberer M
    Recent Results Cancer Res; 2002; 160():195-201. PubMed ID: 12079214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
    Atzpodien J; Fluck M; Reitz M
    Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
    Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
    Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
    Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
    Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.
    Adamina M; Weber WP; Rosenthal R; Schumacher R; Zajac P; Guller U; Frey DM; Oertli D; Zuber M; Heberer M; Spagnoli GC
    Contemp Clin Trials; 2008 Mar; 29(2):165-81. PubMed ID: 17707139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
    J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
    Smith CL; Dunbar PR; Mirza F; Palmowski MJ; Shepherd D; Gilbert SC; Coulie P; Schneider J; Hoffman E; Hawkins R; Harris AL; Cerundolo V
    Int J Cancer; 2005 Jan; 113(2):259-66. PubMed ID: 15386406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.